Renaissance Capital logo

BGMD News

BG Medicine quiet period ends March 15

BG Medicine, which markets a biomarker diagnostic test for heart failure and is developing others, will see its quiet period end on Tuesday, March 15. On February 3, the company raised $35 million by offering 5 million shares at $7, below the original range of...read more

BG Medicine prices IPO at $7, half of its original $13-$15 price range

BG Medicine, which markets a biomarker diagnostic test for heart failure and is developing others, priced its downsized IPO on Thursday. The Waltham, MA-based company raised $35 million by offering 5 million shares at $7 per share. The offering price...read more

BG Medicine refiles for IPO, halves proposed offer price

BG Medicine, which markets a biomarker diagnostic test for heart failure and is developing others, lowered the proposed deal size for its upcoming IPO on Tuesday. The Waltham, MA-based company now plans to raise $33 million by offering 4.75 million shares at an...read more

9 IPOs planned for the week of Dec 13

The following IPOs are expected to price this week:

BG Medicine (BGMD), which markets a biomarker diagnostic test for heart failure and is developing others, plans to...read more